Clinical trial opens enrollment: shifting the PARADIGM with PrimeC by Alon Ben-Noon @EverythingALS
Clinical trial opens enrollment: shifting the PARADIGM with PrimeC by Alon Ben-Noon  @EverythingALS
Uploaded December 2022 | Updated September 2026, 2 weeks ago
Prior to the establishment of NeuroSense, Alon founded MediCan Consulting, a successful consultancy firm which worked and collaborated with many leading pharmaceutical R&D companies, including Mediwound, Chiasma, Teva, Sol-Gel, FutuRx, NeuroDerm and others. The firm’s diligent employees were pioneers, who paved the way to more efficient and accurate work in the industry, mainly in small biotech companies, while coordinating innovative Drug Development Programs, managing operational activities and involved in business development activities.
Clinical trial opens enrollment: shifting the PARADIGM with PrimeC by Alon Ben-NoonDeveloping a Robust Diagnostic Test for ALS by Dr. Sandra Banack from Brain Chemistry Labs.Genetics and ALS: What New Discoveries Mean for You and Your Family with Jennifer Roggenbuck MS, CGCTPN-101 Clinical Trial: for ALS & the C9orf72 Mutation - an Overview of the Trial plus Q&AGene & Cell Therapy ALS Trial: Transplanting stem cells into the motor cortex of patients with ALSFast-Tracking Discovery in ALS:Collaboration, Innovation, and Open ScienceStories and Innovation in ALS Episode# 9:  A Tale of an ALS Reversal with McFinn LovereDr. Ostrow discusses precision medicine in ALS2024 ALS Reversals Update by Dr. Richard Bedlack M.D., Ph.D2022 Outlook for ALSHarnessing The Power of Citizen Research By Mcfinn Lovere, Dave Shulman Michael Thayer Janie GobeliHonoring All Who Served.  Help to Advance Treatments for ALS
Everything ALS |

Clinical trial opens enrollment: shifting the PARADIGM with PrimeC by Alon Ben-Noon

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER